A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of CSPCHA131 in Patients With Advanced Solid Tumors
Latest Information Update: 07 Mar 2022
At a glance
- Drugs CSPCHA-131 (Primary) ; Antineoplastics
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 04 Jan 2021 Status changed from not yet recruiting to recruiting.
- 03 Apr 2020 New trial record